B+
Bull case
25%
Probability
Target price
$8.00
Analysis reference price unavailable
Analysis 2026-05-14 · RankAlpha Sentiment Codex
ATAI
AtaiBeckleyFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$5.50
Analysis reference price unavailable
Analysis 2026-05-14 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$2.50
Analysis reference price unavailable
Analysis 2026-05-14 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-14
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+28.2
Score
AI commentary
This is a T+3 post-earnings monitoring setup rather than a clean re-rate. Primary-source tone was constructive, and the immediate price reaction was modestly positive, with ATAI closing at $4.15 on May 12, 2026 and $4.24 on May 13, 2026. However, no trustworthy consensus EPS/revenue surprise dataset was confirmed from primary sources, and broad post-print analyst revision coverage remains thin, so confidence should stay moderate despite stronger deterministic scores.
RankAlpha Sentiment Codex - 2026-05-14
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-12eventBPL-003 Phase 3 initiation remains the key near-term inflectionHigh impact
The Q1 update reaffirmed that the pivotal ReConnection Phase 3 program for BPL-003 in treatment-resistant depression is on track to start in Q2 2026 following the FDA End-of-Phase 2 meeting, with two studies sized at about 350 and 230 patients and a Week 4 MADRS primary endpoint [#8-K-2026-05-12] [#10-Q-2026-05-12].
2026-08-12eventVLS-01 Phase 2 Elumina topline is the next major non-BPL readoutHigh impact
Management said the Elumina Phase 2 trial of VLS-01 in treatment-resistant depression is progressing as planned with topline results anticipated in Q4 2026, preserving a second meaningful clinical catalyst later this year [#8-K-2026-05-12] [#10-Q-2026-05-12].
2027-05-14catalystCash runway into 2029 supports execution through pivotal milestonesHigh impact
The company reported $209.9 million of cash, cash equivalents and short-term securities at March 31, 2026 and said existing liquidity should fund operations into 2029, which if maintained reduces near-term financing pressure while BPL-003 advances and VLS-01/EMP-01 continue development [#8-K-2026-05-12] [#10-Q-2026-05-12].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-14 • Updated nightlySource: Internal modelMethodology